Drug profile · INN
zonisamide
ZONEGRAN
zonisamide (ZONEGRAN) is a sodium channel alpha subunit blocker. Associated with Amdipharm Mercury (Australia) Pty Limited. Route of administration: oral. Current US regulatory status: approved.
Drug details — zonisamide
- US status
- approved
- Class
- Nervous system (N03)
- Route
- ORAL
- Patents
- 1
- Programs
- 5
- Data quality
- 0.84
Quick answer
zonisamide (ZONEGRAN) is a sodium channel alpha subunit blocker. Associated with Amdipharm Mercury (Australia) Pty Limited. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is zonisamide?
zonisamide (ZONEGRAN) is a sodium channel alpha subunit blocker. Associated with Amdipharm Mercury (Australia) Pty Limited. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for zonisamide?
ZONEGRAN is a marketed brand name for zonisamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of zonisamide?
zonisamide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.